Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dyphylline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 1.00 |
| ▸ | POLB | P06746 | 2/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.68 |
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dyphylline SCHEMBL1816552 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2POLBADORA2BRXFP1 | |
| Dyphylline SCHEMBL8192 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2POLBADORA2BRXFP1 | |
| Dyphylline SCHEMBL27937456 | 0.99 | LMNA (0.97) | LMNASMN1; SMN2POLBADORA2BRXFP1 | |
| Dyphylline SCHEMBL28299816 | 0.95 | LMNA (0.90) | LMNASMN1; SMN2POLBADORA2BRXFP1 | |
| Dyphylline SCHEMBL13724353 | 0.95 | LMNA (0.90) | LMNASMN1; SMN2POLBADORA2BRXFP1 | |
| Dyphylline SCHEMBL5194181 | 0.95 | LMNA (0.90) | LMNASMN1; SMN2POLBADORA2BRXFP1 | |
| Dyphylline SCHEMBL9007973 | 0.93 | SMN1; SMN2 (0.86) | LMNASMN1; SMN2POLBADORA2BRXFP1 | |
| SCHEMBL5265296 | 0.89 | LMNA (0.81) | LMNASMN1; SMN2POLBADORA2BRXFP1 | |
| SCHEMBL10063431 | 0.89 | LMNA (0.80) | LMNASMN1; SMN2POLBADORA2BRXFP1 | |
| Dyphylline SCHEMBL10890402 | 0.89 | LMNA (0.78) | LMNASMN1; SMN2POLBADORA2BRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4807 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120064547-A | Method for detecting dihydroxypropehylline injection | 上海信谊金朱药业有限公司 | 2025-05-30 | — | — | CN | claimed |
| CN-115969780-B | High-stability dihydroxypropehylline injection and preparation method thereof | 杭州沐源生物医药科技有限公司 | 2025-05-02 | — | — | CN | claimed |
| CN-119868268-A | Dihydroxypropyl theophylline injection and preparation method thereof | 江西科为制药有限公司 | 2025-04-25 | — | — | CN | claimed |
| US-20250017878-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | CHRONIC AIRWAY THERAPEUTICS LTD (AU) | 2025-01-16 | — | — | US | claimed |
| CN-119303086-A | Pharmaceutical composition for treating autism | 斯塔利克拉股份有限公司 | 2025-01-14 | — | — | CN | claimed |
| CN-119246866-A | Total bilirubin dry detection and analysis assembly and preparation method thereof | 英科新创(厦门)科技股份有限公司 | 2025-01-03 | — | — | CN | claimed |
| CN-118415983-B | Sustained-release dihydroxypropyltheophylline nasal spray and preparation method thereof | 海南钧华医疗科技有限公司 | 2024-11-26 | — | — | CN | claimed |
| WO-2024189434-A1 | USE OF NADOLOL TO TREAT PULMONARY SYMPTOMS ASSOCIATED WITH INFECTIONS WITH SARS-CoV-2 | CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) | 2024-09-19 | — | — | WO | claimed |
| CN-118634187-A | Dihydroxypropyl theophylline injection and preparation method thereof | 上海信谊金朱药业有限公司 | 2024-09-13 | — | — | CN | claimed |
| CN-118415983-A | Sustained-release dihydroxypropyltheophylline nasal spray and preparation method thereof | 海南钧华医疗科技有限公司 | 2024-08-02 | — | — | CN | claimed |
| US-4728513-A | HEAT TREATED FOR STORAGE STABILITY | ZYMA SA (CH) | 1988-03-01 | — | — | US | claimed |
| EP-0250374-A1 | Therapeutic system for controlled release of drugs | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.a. (IT) | 1987-12-23 | — | — | EP | claimed |
| EP-0213083-A2 | Controlled release tablet | Zyma SA (CH) | 1987-03-04 | — | — | EP | claimed |
| EP-0033036-B1 | CATALYST COMPONENT | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1984-07-04 | — | — | EP | claimed |
| US-4325835-A | Catalyst component | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1982-04-20 | — | — | US | claimed |
| US-4324691-A | Catalyst component | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1982-04-13 | — | — | US | claimed |
| EP-0033036-A1 | Catalyst component | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1981-08-05 | — | — | EP | claimed |
| EP-0026986-A1 | Polymerisation catalysts and process for the homo- or co-polymerisation of alpha-olefins | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1981-04-15 | — | — | EP | claimed |
| EP-0026987-A1 | Polymerisation catalysts and process for the homo- or co-polymerisation of alpha-olefins | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1981-04-15 | — | — | EP | claimed |
| US-4130432-A | BIOCIDES | CIBA-GEIGY CORPORATION (US) | 1978-12-19 | — | — | US | claimed |